Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their interactions with remdesivir, the only direct-acting antiviral approved for COVID-19 treatment. HCV PIs showed differential potency in short-term treatment assays based on the detection of SARS-CoV-2 spike protein in Vero E6 cells. Linear PIs boceprevir, telaprevir, and narlaprevir had 50% effective concentrations (EC50) of ∼40 μM. Among the macrocyclic PIs, simeprevir had the highest (EC50, 15 μM) and glecaprevir the lowest (EC50, >178 μM) potency, with paritaprevir, grazoprevir, voxilaprevir, vaniprevir, danoprevir, and deldeprevir in between. Acyclic PIs asunaprevir and faldaprevir had EC50s of 72 and 23 μM, respectively. ACH-806, inhibiting the HCV NS4A protease cofactor, had an EC50 of 46 μM. Similar and slightly increased PI potencies were found in human hepatoma Huh7.5 cells and human lung carcinoma A549-hACE2 cells, respectively. Selectivity indexes based on antiviral and cell viability assays were highest for linear PIs. In short-term treatments, combination of macrocyclic but not linear PIs with remdesivir showed synergism in Vero E6 and A549-hACE2 cells. Longer-term treatment of infected Vero E6 and A549-hACE2 cells with 1-fold EC50 PI revealed minor differences in the barrier to SARS-CoV-2 escape. Viral suppression was achieved with 3- to 8-fold EC50 boceprevir or 1-fold EC50 simeprevir or grazoprevir, but not boceprevir, in combination with 0.4- to 0.8-fold EC50 remdesivir; these concentrations did not lead to viral suppression in single treatments. This study could inform the development and application of protease inhibitors for optimized antiviral treatments of COVID-19.

TidsskriftAntimicrobial Agents and Chemotherapy
Udgave nummer9
Sider (fra-til)1-24
Antal sider24
StatusUdgivet - 17 aug. 2021

ID: 66134842